What this means
Experts wrote a guide on weighing benefits and risks, such as muscle loss, when older adults take these drugs. It is advice built from example patient cases, not a new study testing the drugs.
Plain-English summary written by an AI model from the abstract and a science-news story about it (Medical Xpress). The original is below.
- Who it was tested in
- No people tested; an expert guide using example patient cases
- Kind of research
- A study
The science
- Original title
- Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.
- Authors
- Wisdom EM, Goldlist K, Lieber SB et al.
- Journal
- Journal of the American Geriatrics Society
- Published
- Oct 29, 2026
- Study type
- Study
- PMID
- 42952307 ↗
Abstract
Obesity medications that act through gut-derived hormonal pathways include glucagon-like peptide-1 receptor agonists (GLP-1), dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GLP-1/GIP), and emerging triple glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor agonists. These therapies are increasingly prescribed for weight management and glycemic control, as well as for their cardiometabolic and renal benefits. While these medications offer substantial benefits to patients across multiple health conditions, their use in older adults warrants heightened scrutiny. Older adults face increased risks of sarcopenia and frailty, and evidence from major clinical trials suggests that a substantial proportion of medication-associated weight loss agents may result in loss of lean mass, potentially posing risks for this population. Other adverse effects that may be more consequential in older adults include dehydration, malnutrition, perioperative aspiration, and fat-predominant weight regain after discontinuation. This paper provides a clinically oriented framework to guide prescribing decisions for older adults. Drawing on patient scenarios from common geriatric contexts, including frailty, cognitive impairment, glucocorticoid use, and surgical planning, we propose prescribing approaches that optimize therapeutic benefits while mitigating potential harms. We integrate these recommendations within the Geriatrics 5Ms Framework (Mind, Mobility, Medications, Multicomplexity, and Matters Most) to contextualize treatment within geriatrics practice. Lifestyle co-interventions, particularly resistance training, adequate protein intake, and ongoing functional monitoring, emerge as essential components for older adults receiving these therapies. We also discuss identifying priority areas for future research, including age-stratified clinical trials and the routine inclusion of body composition and physical function outcomes.
Wisdom EM, Goldlist K, Lieber SB et al. Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing. Journal of the American Geriatrics Society. 2026. doi:10.1111/jgs.70769. PMID: 42952307. https://pubmed.ncbi.nlm.nih.gov/42952307/
In the news
How science news reported this paper. We link to these stories; we don't write or endorse them.
Related research
Effects of an exercise prescription system (ACTIVE) on physical function in community-dwelling older adults: protocol for a single-centre, assessor-blinded,…
ABSTRACT Introduction China is experiencing rapid population ageing and has the largest elderly population in the world.
Short exercise and breathing program before heart surgery tested in 36 patients
A short pre-surgery program of breathing work, strength training, and education was doable for most patients. It did not improve walking capacity, and larger studies are needed to confirm other benefits.
Strength training on unstable surfaces gave small gains on two thinking tests in older adults
After 24 weeks, the training group recalled about 0.7 more numbers and named 1.2 more words than a gentle-exercise group. There was no difference on other thinking or memory tests, and it is unclear if this matters in daily life.
Longitudinal association of social participation with locomotive syndrome among Japanese older adults: a 5-year community-based study.
BACKGROUND: Locomotive syndrome (LS), characterized by reduced mobility due to musculoskeletal impairment, is a major contributor to disability and long-term care dependency in aging populations.
Aging exacerbates muscle loss induced by semaglutide treatment in female mice.
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity.
Hospital exercise in bed may help daily function in pneumonia patients
Patients who pedaled in bed had better daily self-care scores three months later than those given usual care. Other measures, like grip and walking steps, showed no clear change.
See all research on GLP-1 drugs →
